Pharma

Vertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment

Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy.

Merck Partners with Hansoh Pharma on Oral GLP-1 Receptor Agonist for Type 2 Diabetes

Merck has entered into an exclusive global license agreement with Hansoh Pharma to develop and commercialize HS-10270, an investigational oral GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity.

MRI scans of the lumbosacral spine. MRI shows degenerative changes in the spine, hernia of the lumbar discs and compression of the nerve roots

Astellas and Avexis Collaborate on Gene Therapy for Spinal Muscular Atrophy

Astellas Pharma partners with AveXis to develop and commercialize AVXS-101, a promising gene therapy for Spinal Muscular Atrophy (SMA), aiming to expand treatment options for this rare and life-threatening genetic disorder.

Roche’s $1.5 Billion Punt on Poseida

Roche’s $1.5 billion acquisition of Poseida Therapeutics positions the company to lead the development of scalable, off-the-shelf CAR-T therapies, potentially transforming cancer treatment by improving accessibility, affordability, and targeting both hematologic and solid tumors.

Novo Nordisk’s CagriSema and the Competitive Dynamics in the Obesity Drug Market

Can CagriSema increase the efficacy of obesity treatment and preserve Novo Nordisk's leading position in the market?

FDA Approves NGS-Based Companion Diagnostic for Targeted Therapy in Grade 2 IDH-Mutant Glioma Patients

FDA approves Thermo Fisher's NGS-based companion diagnostic for targeted therapy in patients with grade 2 IDH-mutant glioma